GEN InCode
GENinCode is a company dedicated to transforming cardiovascular health through genetics by providing advanced genomic testing, risk assessment tools, and personalized treatment pathways. With over 15 years of research and collaboration with leading institutions, GENinCode aims to prevent, diagnose, and treat cardiovascular disease using innovative technology that combines monogenic, polygenic, clinical algorithms, and artificial intelligence. The company operates in the UK, US, and Europe, and its products are validated by scientific and clinical teams to support healthcare practitioners in making informed decisions to improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
GEN InCode
Oxford Science Park, John Eccles House, Robert Robinson Avenue, Oxford, OX4 4GP, UK
Patents
Products
Clinical genomic test suite for cardiovascular risk
A suite of in-vitro diagnostic tests that assess coronary genetic load (polygenic), monogenic causes of hypercholesterolemia and genetic thrombophilia, delivered from laboratory workflows and integrated into clinical reports.
Clinical genomic test suite for cardiovascular risk
A suite of in-vitro diagnostic tests that assess coronary genetic load (polygenic), monogenic causes of hypercholesterolemia and genetic thrombophilia, delivered from laboratory workflows and integrated into clinical reports.
Services
Clinical laboratory testing that combines targeted genotyping/sequencing, polygenic risk scoring and clinical data to produce individualized cardiovascular risk assessments and management recommendations.
Online portal for healthcare practitioners to request tests, capture clinical and genetic information, manage sample shipments, track testing status and retrieve reports.
Laboratory testing services operated under CLIA certification and regional licensing to enable testing and report delivery across the United States and other jurisdictions where accredited.
Clinical utility consultation, workflow design, ordering assistance, kit and logistics support, and lab service agreement setup for healthcare customers.
Coordination of early access programs, commercial partnerships and collaboration agreements to support market entry and scale-up.
Clinical laboratory testing that combines targeted genotyping/sequencing, polygenic risk scoring and clinical data to produce individualized cardiovascular risk assessments and management recommendations.
Online portal for healthcare practitioners to request tests, capture clinical and genetic information, manage sample shipments, track testing status and retrieve reports.
Laboratory testing services operated under CLIA certification and regional licensing to enable testing and report delivery across the United States and other jurisdictions where accredited.
Clinical utility consultation, workflow design, ordering assistance, kit and logistics support, and lab service agreement setup for healthcare customers.
Coordination of early access programs, commercial partnerships and collaboration agreements to support market entry and scale-up.
Expertise Areas
- Genomic risk assessment for cardiovascular disease
- Polygenic risk score development and application
- Monogenic variant testing for cardiometabolic disorders
- Molecular diagnostics and targeted genotyping
Key Technologies
- Polygenic risk scoring
- Monogenic variant genotyping
- qPCR-based SNP genotyping
- Genotyping and sequencing
News & Updates
A collaboration to advance familial hypercholesterolemia research and testing.
Presentation of the latest research and developments in cardiovascular genetic risk assessment.
A new study offering hope in combating coronary heart disease using genetic risk assessment.
A collaboration to advance familial hypercholesterolemia research and testing.
Presentation of the latest research and developments in cardiovascular genetic risk assessment.
A new study offering hope in combating coronary heart disease using genetic risk assessment.